Week in Review: Hua Medicine to Raise $200 Million Through Fundings and IPO for Oral Diabetes Drug

Deals and Financings Hua Medicine will raise $200 million in fundings and an IPO to complete clinical development of its novel oral diabetes 2 treatment and commercialize the drug;  Shanghai Fosun Pharma announced a $50 million US joint venture, which consists of Fosun Pharma USA and Fosun International;  Suzhou Kintor Pharma raised $44 million in a funding to underwrite development of its novel drug portfolio;  Lepu Medical Technology ( Beijing ) acquired a 13% stake in Australia 's Viralytics via a $23.3 million private placement; Fosun Pharma acquired China rights to a novel Parkinson's treatment from Portugal 's BIAL in an $18 million agreement; Biostage of Massachusetts raised $4.2 million in a private placement from China investors for its bioengineered organ implants; Ferring Pharma, a Swiss company, will collaborate with the Chinese Academy of Sciences to develop new reproductive medicine and women’s health medicines; WuXi AppTec formed a JV with the Mayo Clinic to co-develop novel esoteric clinical diagnostic services for China and the world; Ping An Health Technology signed a MOU with Varian, a US maker of radiology machines that treat and manage cancer, to expand cancer care access in China ; Shanghai Sinobioway Sunterra Biotech will use F1 Oncology's technology for gene therapy and cell therapy manufacturing; The venture capital arm of Shenzhen's HEC Pharm, will make several investments in Enlyton, a US company developing novel imaging contrast agents; Ally Bridge Group of Hong Kong will team up with Shenzhen's LifeTech Scientific to invest in medical device companies; Simcere Pharma of Nanjing acquired China rights to develop three bi-specific immunoncology antibodies from Merus, a Dutch biotech ; Beijing 's BeiGene licensed multi-year rights to use Harbour BioMed's H2L2 transgenic mouse platform for drug discovery; Berry Genomics of Beijing will collaborate with California 's 10X Genomics to develop next-gen noninvasive prenatal tests; Government and Regulatory   The CFDA plans to double its drug application reviewers from 800 presently to 1,600 by 2020, a considerable increase from 170 in 2015; Singapore 's Aslan Pharma now expects China approval of varlitinib one year earlier than its previous schedule, due to the CFDA's faster approval regulations; Trials and Approvals   3SBio reported the CFDA approved Bydureon®, its once-weekly GLP-1 receptor agonist for type 2 diabetes; Suzhou 's Ascentage Pharma said the CFDA accepted its IND submission for APG-1387, which aims to restore apoptosis as a treatment for hepatitis B. Stock Symbols: (SHA: 600196; HK: 2196) (HK: 656) (SHZ: 300003) (ASX: VLA, OTC: VRACY) (OTCQB: BSTG/BSTGD) (NYSE: VAR) (HK: 1302) (NSDQ: MRUS) (NSDQ: BGNE) (SHZ: 000710) (TT: 6497) (HK: 01530) Share this with colleagues: // //